S Khan1, Y M Tan, A John, J Isaac, S Singhvi, P Guest, D F Mirza. 1. Liver Unit (Liver Transplantation and Hepatobiliary Surgery), University Hospital Birmingham, Queen Elizabeth, Edgbaston, UK. saboor.711@gmail.com
Abstract
AIM: To assess the use of positron emission tomography combined with computerized tomography (CT-PET) with fluoro-18-2-deoxy-d-glucose ((18)F-FDG) to identify hyper-metabolic tumours, especially colorectal metastases (CRM). METHODS: Patient particulars, diagnoses and clinical outcome for each patient were studied. Twenty-three patients underwent CT-PET, 10 males and 13 females, median age 59 (range 34-72). Fourteen patients presented with primary liver CRM and nine had undergone previous liver resections. Indications for CT-PET included; suspected extrahepatic disease in 13/23 patients, possible hepatic recurrence 5/23 and clinical suspicion in 8/23 patients. RESULTS: Seven patients had a major impact on their management. Unexpected (not seen on CT) findings in the CRM group included, 7/23 (30%) patients with extrahepatic disease, 3/23 with hepatic metastases, 8/23 suspected of having liver or distant metastases on CT had a negative study. A clinical decision, based on the CT-PET report, could be undertaken in 21/23 patients. CONCLUSION: CT-PET is useful in patients with CRM where conventional imaging presents dilemmas such as: assessment of suspected extrahepatic disease, recurrence in liver, patients with advanced or perforated initial tumours.
AIM: To assess the use of positron emission tomography combined with computerized tomography (CT-PET) with fluoro-18-2-deoxy-d-glucose ((18)F-FDG) to identify hyper-metabolic tumours, especially colorectal metastases (CRM). METHODS:Patient particulars, diagnoses and clinical outcome for each patient were studied. Twenty-three patients underwent CT-PET, 10 males and 13 females, median age 59 (range 34-72). Fourteen patients presented with primary liver CRM and nine had undergone previous liver resections. Indications for CT-PET included; suspected extrahepatic disease in 13/23 patients, possible hepatic recurrence 5/23 and clinical suspicion in 8/23 patients. RESULTS: Seven patients had a major impact on their management. Unexpected (not seen on CT) findings in the CRM group included, 7/23 (30%) patients with extrahepatic disease, 3/23 with hepatic metastases, 8/23 suspected of having liver or distant metastases on CT had a negative study. A clinical decision, based on the CT-PET report, could be undertaken in 21/23 patients. CONCLUSION: CT-PET is useful in patients with CRM where conventional imaging presents dilemmas such as: assessment of suspected extrahepatic disease, recurrence in liver, patients with advanced or perforated initial tumours.
Authors: G Kong; C Jackson; D M Koh; V Lewington; B Sharma; G Brown; D Cunningham; G J R Cook Journal: Eur J Nucl Med Mol Imaging Date: 2008-03-18 Impact factor: 9.236
Authors: G Li Destri; F Di Benedetto; B Torrisi; T R Portale; F Mosca; R Vecchio; A Di Cataldo; S Puleo Journal: HPB (Oxford) Date: 2008 Impact factor: 3.647
Authors: Monique Maas; Iris J G Rutten; Patty J Nelemans; Doenja M J Lambregts; Vincent C Cappendijk; Geerard L Beets; Regina G H Beets-Tan Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-06 Impact factor: 9.236
Authors: I Sobhani; E Tiret; R Lebtahi; T Aparicio; E Itti; F Montravers; C Vaylet; P Rougier; T André; J M Gornet; D Cherqui; C Delbaldo; Y Panis; J N Talbot; M Meignan; D Le Guludec Journal: Br J Cancer Date: 2008-02-26 Impact factor: 7.640